weak quarter below-market sale growth trend
continu margin impact one-off cost
mn relat on-board train payment relat
expans field forc chang disclosur split
stride brand acquisit longer
eri announc entri trade gener surpris given
overhang channel margin cap invest low segment
may prove distract also get lower multipl
eri acquir vildagliptin brand zome price
tablet eri acquir brand sale around
mn annualis sale reduc mn
sale growth doubl digit help zome
contribut anoth in-licens drug rariset
cut ep factor weak
sale lower margin given signific expans field forc
cut target price
ep eri also announc re-organis busi five
sbuscardio-metabol acut new busi
growth continu sluggish littl sign recoveri
eri report modest yoy growth revenu
much lower report peer concern
one-off sustain trend four quarter evidenc
growth yoy eri also stop disclosur
revenu break-up stride brand acquisit
report ebitda impact one-off
expans field forc report ebitda margin
normalis ebitda low even post
adjust mn one-off expens eri attribut
on-board train payment relat expans field
forc eri ad mr take total count current
involv divis promot zome
vildagliptin brand eri in-licens novarti mn
busi organis restructur drive focu announc
entri trade gener eri announc restructur
divis five sbuscardio-metabol acut new
busi acut sbu hous gynecolog orthoped gi
brand restructur done drive differenti focu
dedic leadership key therapeut area eri also
announc entri trade gener segment
trade gener entri consolid acut segment
margin-dilut trade gener segment aim augment
acut portfolio eri mention alreadi sourc drug
push trade gener channel higher
skew toward drug potenti sold via over-the-counter eri expect
add drug near term alreadi hire mr
plan add mr time launch drug
manufactur in-hous like yield gross margin
ebitda margin steadi state trade gener
busi would start gener revenu
key drug like add growth eri acquir
vildagliptin brand zome price
estimate pot chg tp
number share mn
chg prev ep
tablet eri acquir brand sale mn
annualis sale reduc mn sale growth
doubl digit help zome contribut anoth
in-licens drug rariset margin initi go dilut
eri institut larg field forc promot brand
guwahati plant account revenu
guwahati facil current cater total eri revenu
expect increas nutraceut
alreadi manufactur facil soft gel product also like
shift
annualis revenu mr
annualis revenu mr top brand constitut two-
third total revenu bn post buy-back bn
loan pre-pay zome in-licens bn
figur sale growth weak yoy
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid report singl factor make invest
charl martineau pm univers toronto compani mention price
anubhav aggarw certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view
express report
price rate histori abt
signifi initi assumpt coverag
price rate histori eri lifesci ltd eri bo
signifi initi assumpt coverag
price rate histori novarti novn
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
charl martineau pm univers toronto under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst
coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun octob
canadian well european exclud turkey rate base stock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres attract neutral less
attract underperform least attract invest opportun latin america turkey asia exclud japan australia
stock rate base stock total return rel averag total return relev countri region benchmark india
bse sensex index prior octob canadian rate base stock absolut total return potenti
current share price rel attract stock total return potenti within analyst coverag univers australian
new zealand stock expect total return calcul includ roll dividend yield outperform rate assign
greater equal under-perform less equal neutral may assign
overlap rate rang allow analyst assign rate put context associ risk
prior may rang outperform under-perform rate overlap neutral threshold
oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
circumst
rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate
invest view equiti secur compani relat product
volatil indic stock defin volatil stock price move month least
past month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector
credit suiss distribut stock rate bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform
